Skip to main content

Semaglutide vs Cagrilintide

Both Semaglutide and Cagrilintide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Semaglutide

Evidence A+

Semaglutide (Ozempic / Wegovy)

A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.

View full Semaglutide profile →

Cagrilintide

Evidence A

Cagrilintide (long-acting amylin analog)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

View full Cagrilintide profile →

Side-by-Side

AttributeSemaglutideCagrilintide
Evidence GradeA+A
FDA StatusFDA-approved for weight management and type 2 diabetesNot FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress
Typical Dose0.25–2.4 mg weekly (subcutaneous injection)Trial range: 0.16–4.5 mg weekly (subcutaneous)
Clinics Indexed2,2858
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Semaglutide

  • Significant weight loss
  • Appetite suppression
  • Blood sugar control
  • Cardiovascular benefit

Key reported benefits — Cagrilintide

  • Amylin pathway weight loss
  • Synergy with GLP-1
  • Lower-dose tolerability

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons